Incidence, clinical classification and risk factors of cyclosporin A-induced liver injury in allogeneic haematopoietic stem cell transplant recipients.
Br J Clin Pharmacol
; 90(11): 2910-2919, 2024 Nov.
Article
em En
| MEDLINE
| ID: mdl-39054805
ABSTRACT
AIMS:
There is limited real-world data on cyclosporin A (CsA)-induced liver injury (CILI). This study aims to investigate the incidence, clinical classification and risk factors of CILI, thereby providing evidence to inform the treatment of CILI.METHODS:
Inpatients receiving haematopoietic stem cell transplantation (HSCT) and treated with CsA were included. Patient information was collected to assess suspicious CILI by the Roussel Uclaf causality assessment method (RUCAM) scale. We evaluated the pattern and severity of CILI. The independent risk factors of CILI were identified by multivariable logistic regression.RESULTS:
A total of 216 allogeneic HSCT (allo-HSCT) recipients were included in this study. The incidence of CILI was 15.3% (95% confidence interval [CI] 10.4%-20.1%). Among these cases, 84.8% displayed a hepatocellular pattern, and 90.9% of CILI was of mild severity. Baseline alanine aminotransferase (ALT) level (OR = 1.030, 95% CI 1.008-1.053, P = .008) and trough concentration level of CsA (OR = 1.007, 95% CI 1.002-1.012, P = .009) were identified as independent risk factors for CILI.CONCLUSIONS:
The incidence of CILI in allo-HSCT recipients is notably high. Recipients with elevated baseline ALT levels and higher exposure to CsA are more susceptible to developing CILI.Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Ciclosporina
/
Transplante de Células-Tronco Hematopoéticas
/
Doença Hepática Induzida por Substâncias e Drogas
/
Imunossupressores
Limite:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Br J Clin Pharmacol
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
China